Global reach Remidio has CE and FDA cleared devices with deployments in 40+ countries and 16 million+ patient screenings, indicating a scalable international sales opportunity across diverse healthcare markets.

Systemic disease angle Beyond eye care, Remidio’s Oculomics platform aims to detect systemic diseases (CVD, CKD, liver conditions) using retinal imaging, opening upsell possibilities with hospitals and payers seeking preventive, cross-domain AI diagnostics.

Strategic partnerships Recent collaborations and grants, including Gates Foundation funding for maternal health applications and integration with RetinaRisk, suggest momentum for co-development and joint go-to-market initiatives with public health and tech partners.

Funding momentum Total funding of 18M and a $25M financing event signal strong investor confidence and potential for scale, enabling expanded sales teams, training, and regional expansion in high-growth LMIC and developed markets.

Recognition and awards Top-tier industry recognition, including first-place finishes in MedTech challenges and AI impact awards, enhances credibility with buyers and can shorten sales cycles in competitive R&D and hospital procurement processes.